Fit for Filing
About FFF
The scope of Fit for Filing (FFF) is to develop best principles on how to design and deliver an academic or academic & industry collaborative trial with a dataset that can be included in a package for regulatory filing.
Objectives of the FFF working group are:
- Define the barriers and propose solutions to ensure academic trial datasets are usable for regulatory submissions;
- Define how industry can support academic/healthcare institutions to deliver fit for filing clinical trials.
The Working Group has been established by balancing the involvement of the relevant target groups: it includes 3 Academia, 3 Pharma, 2 Regulators and 1 Patient Advocate.
Who we are
The Fit For Filing WG is currently co-led by Prof. Pam Kearns (University of Birmingham) & Elly Barry (Day One Biopharmaceuticals).
The Working group brings together representatives of four stakeholder groups:
Academia (clinicians and researchers):
Bram De Wilde (Ghent University Hospital), Beth Fox (Children’s Hospital Philadelphia)
Regulators:
Greg Reaman (FDA), Dominik Karres (EMA)
Industry (pharmaceutical companies and biotechs):
Elly Barry (Day One Biopharmaceuticals), Mark Kieran (Day One Biopharmaceuticals)
Advocacy (parents, patients and survivors):
Donna Ludwinski (Solving kids Cancer)
For more information, please contact the working group lead:
Fit for Filing Working Group Secretariat: carole.lecinse@gustaveroussy.fr